GlassScriptPhysician profile
Missy Dishman
NPI 1598223984
$5,573.81
in general payments reported to CMS, 2019-2025
50 companies · $99.11 in 2025
The $99.11 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $130 · 2021: $755 · 2022: $980 · 2023: $1,317 · 2024: $2,294 · 2025: $99.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,365 · Education: $345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,365.29 |
| Education | $344.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $945.19 | 2021-2025 | Erleada, Tecvayli, Darzalex |
| Abbvie INC. | $663.51 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $485.63 | 2023-2024 | Lynparza, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $423.94 | 2024 | Opdivo, Reblozyl, Eliquis |
| Lilly USA, LLC | $268.05 | 2023-2024 | Retevmo |
| Merck Sharp & Dohme LLC | $225.81 | 2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $192.74 | 2023-2024 | |
| Incyte Corporation | $180.89 | 2023-2024 | Jakafi |
| Jazz Pharmaceuticals INC. | $178.82 | 2023-2024 | |
| Genzyme Corporation | $138.04 | 2024 | |
| Amgen INC. | $119.36 | 2021-2022 | |
| Celgene Corporation | $116.86 | 2022-2025 | Reblozyl |
| Pfizer INC. | $114.03 | 2021-2024 | |
| Scilex Pharmaceuticals INC. | $113.70 | 2020 | |
| Stemline Therapeutics INC. | $111.70 | 2024 | Orserdu |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Missy Dishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.